PMV Pharmaceuticals PYNNACLE Phase I Data Of Rezatapopt In Advanced Ovarian Cancer Featured In Oral Presentation At 2024 SGO Annual Meeting On Women's Cancer
Portfolio Pulse from Benzinga Newsdesk
PMV Pharmaceuticals presented promising Phase 1 data of rezatapopt in advanced ovarian cancer at the 2024 SGO Annual Meeting. The study showed a confirmed partial response in 7 out of 15 patients, with a median duration of response of seven months and a favorable safety profile. Rezatapopt targets TP53 Y220C mutation and KRAS wild-type in advanced solid tumors and is advancing to a registrational Phase 2 study.
March 18, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PMV Pharmaceuticals' promising Phase 1 data of rezatapopt in advanced ovarian cancer was highlighted at the 2024 SGO Annual Meeting, showing significant efficacy and safety.
The positive Phase 1 data of rezatapopt in advanced ovarian cancer, including a high response rate and favorable safety profile, are likely to generate investor optimism about PMV Pharmaceuticals' pipeline. This could lead to increased investor confidence and potentially a positive impact on PMVP's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100